Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Beta Bionics Beta Bionics develops and commercializes automated insulin delivery systems, including the iLet insulin pump and a pipeline of diabetes devices and drug-device combinations. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems that simplify and improve diabetes management for people living with type 1 and type 2 diabetes. What are the underlying business or industry changes driving this perspective?Read more
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
